CY1116706T1 - Εμβολια προϊοντος συζευξης αντιγονου πολυσακχαριδιου γλυκολιπιδιου - Google Patents

Εμβολια προϊοντος συζευξης αντιγονου πολυσακχαριδιου γλυκολιπιδιου

Info

Publication number
CY1116706T1
CY1116706T1 CY20151100848T CY151100848T CY1116706T1 CY 1116706 T1 CY1116706 T1 CY 1116706T1 CY 20151100848 T CY20151100848 T CY 20151100848T CY 151100848 T CY151100848 T CY 151100848T CY 1116706 T1 CY1116706 T1 CY 1116706T1
Authority
CY
Cyprus
Prior art keywords
vaccines
conjugate vaccine
antigen conjugate
glycolipid antigen
pathogens
Prior art date
Application number
CY20151100848T
Other languages
English (en)
Inventor
Peter H Seeberger
Pierre Stallforth
Libero Gennaro De
Marco Cavallari
Original Assignee
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/002277 external-priority patent/WO2013178236A1/en
Application filed by MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. filed Critical MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.
Publication of CY1116706T1 publication Critical patent/CY1116706T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η παρούσα εφεύρεση αφορά στο πεδίο σύνθεσης και αξιολόγησης βιολογικώς μιας νέας κατηγορίας εμβολίων που βασίζονται σε υδατάνθρακα. Τα νέα εμβόλια συνίστανται από μια πολυ-μορφωματική δομή η οποία επιτρέπει την εφαρμογή του εμβολίου σε ένα ευρύ φάσμα παθογόνων. Η μέθοδος αυτή επιτρέπει παρασκευή εμβολίων έναντι όλων των παθογόνων που εκφράζουν ανοσογονικά αντιγόνα υδατάνθρακα. Καθώς δεν απαιτείται σύζευξη των αντιγονικών υδατανθράκων προς πρωτεΐνες, το συζευγμένο εμβόλιο είναι ιδιαιτέρως θερμο-σταθερό. Δεν απαιτείται ψύξη, ένα σημαντικό μειονέκτημα των εμβολίων που βασίζονται σε πρωτεΐνη.
CY20151100848T 2012-03-19 2015-09-25 Εμβολια προϊοντος συζευξης αντιγονου πολυσακχαριδιου γλυκολιπιδιου CY1116706T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2012054848 2012-03-19
PCT/EP2012/002277 WO2013178236A1 (en) 2012-05-26 2012-05-26 Carbohydrate-glycolipid conjugate vaccines
EP13710422.0A EP2827899B1 (en) 2012-03-19 2013-03-19 Polysaccharide antigen-glycolipid conjugate vaccines

Publications (1)

Publication Number Publication Date
CY1116706T1 true CY1116706T1 (el) 2017-03-15

Family

ID=47901120

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100848T CY1116706T1 (el) 2012-03-19 2015-09-25 Εμβολια προϊοντος συζευξης αντιγονου πολυσακχαριδιου γλυκολιπιδιου

Country Status (23)

Country Link
US (1) US10588962B2 (el)
EP (1) EP2827899B1 (el)
JP (2) JP5933106B2 (el)
KR (1) KR101675657B1 (el)
CN (1) CN104321079A (el)
AR (1) AR090386A1 (el)
AU (1) AU2013237497B2 (el)
BR (1) BR112014023193A2 (el)
CA (1) CA2866978C (el)
CY (1) CY1116706T1 (el)
DK (1) DK2827899T3 (el)
ES (1) ES2551599T3 (el)
HK (1) HK1205682A1 (el)
HU (1) HUE028144T2 (el)
IL (1) IL234604A (el)
MX (1) MX337202B (el)
PL (1) PL2827899T3 (el)
PT (1) PT2827899E (el)
RU (1) RU2649009C2 (el)
SG (1) SG11201405646TA (el)
SI (1) SI2827899T1 (el)
TW (1) TWI633112B (el)
WO (1) WO2013139803A1 (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2851092A1 (en) 2013-09-18 2015-03-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Protein and peptide-free synthetic vaccines against streptococcus pneumoniae type 3
WO2016152980A1 (ja) * 2015-03-24 2016-09-29 国立大学法人岐阜大学 オリゴヌクレオチド誘導体及びそれを用いたオリゴヌクレオチド構築物並びにそれらの製造方法
CN106565800B (zh) * 2015-10-08 2019-08-13 中国人民解放军第二军医大学 三糖对甲氧基苯酚苷类化合物及其制备方法
TWI732825B (zh) * 2016-05-20 2021-07-11 日商王子控股股份有限公司 圖案形成用定向自組裝組成物、圖案形成用定向自組裝組成物用單體及圖案形成方法
CN106620682A (zh) * 2017-01-19 2017-05-10 华中师范大学 一种脂质体疫苗制剂及其用途和生产IgG抗体的方法
JP7218358B2 (ja) 2017-09-07 2023-02-06 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎球菌多糖体および免疫原性多糖体－キャリアタンパク質コンジュゲートでのその使用
CN107955082B (zh) * 2017-12-11 2019-05-10 江南大学 幽门螺旋杆菌脂多糖外核心八糖的制备方法
CN111760021B (zh) * 2020-05-18 2023-06-16 广州中医药大学(广州中医药研究院) 一种含有α-半乳糖神经酰胺类似物与糖抗原的缀合物及其制备方法和应用
CN111760020B (zh) * 2020-05-18 2023-05-26 广州中医药大学(广州中医药研究院) 一种缀合物及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
FI20010118A (fi) * 2001-01-19 2002-07-20 Carbion Oy Uudet helicobacter pylori reseptorit ja niiden käyttö
EP1434859A2 (en) 2001-07-25 2004-07-07 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
US8273357B2 (en) * 2004-07-16 2012-09-25 Massachusetts Institute Of Technology Antigen-carbohydrate conjugates
AU2005280163B2 (en) 2004-08-27 2011-11-24 Albert Einstein College Of Medicine, Inc. Ceramide derivatives as modulators of immunity and autoimmunity
US8022043B2 (en) 2004-08-27 2011-09-20 Albert Einstein College Of Medicine Of Yeshiva University Ceramide derivatives as modulators of immunity and autoimmunity
GB0419846D0 (en) * 2004-09-07 2004-10-13 Chiron Srl Vaccine adjuvants for saccharides
US7923013B2 (en) * 2004-12-28 2011-04-12 The Rockefeller University Glycolipids and analogues thereof as antigens for NKT cells
WO2007051004A2 (en) 2005-10-28 2007-05-03 The Brigham And Women's Hospital, Inc. Conjugate vaccines for non-proteinaceous antigens
ES2574825T3 (es) * 2007-10-12 2016-06-22 Luigi Panza Análogos de glicolípidos útiles como inmunoadyuvantes
EP2058011A1 (en) * 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
WO2010083728A1 (en) * 2009-01-23 2010-07-29 Dapeng Zhou Nanoparticle formulated glycolipid antigens for immunotherapy
US8455565B2 (en) 2011-05-18 2013-06-04 3M Innovative Properties Company Disulfide monomers comprising ethylenically unsaturated groups suitable for dental compositions

Also Published As

Publication number Publication date
KR20140138996A (ko) 2014-12-04
IL234604A (en) 2016-03-31
MX2014011242A (es) 2015-03-09
ES2551599T3 (es) 2015-11-20
MX337202B (es) 2016-02-17
PT2827899E (pt) 2015-11-18
JP2015514067A (ja) 2015-05-18
AR090386A1 (es) 2014-11-05
BR112014023193A2 (pt) 2017-08-01
US20150238597A1 (en) 2015-08-27
CA2866978C (en) 2019-01-29
HUE028144T2 (en) 2016-11-28
JP6235648B2 (ja) 2017-11-22
KR101675657B1 (ko) 2016-11-11
CN104321079A (zh) 2015-01-28
CA2866978A1 (en) 2013-09-26
AU2013237497A1 (en) 2014-10-02
US10588962B2 (en) 2020-03-17
JP2016183166A (ja) 2016-10-20
PL2827899T3 (pl) 2015-12-31
SG11201405646TA (en) 2014-10-30
RU2014142043A (ru) 2016-05-20
WO2013139803A1 (en) 2013-09-26
EP2827899B1 (en) 2015-08-05
AU2013237497B2 (en) 2016-05-12
JP5933106B2 (ja) 2016-06-08
TW201343662A (zh) 2013-11-01
HK1205682A1 (en) 2015-12-24
TWI633112B (zh) 2018-08-21
DK2827899T3 (en) 2015-10-26
EP2827899A1 (en) 2015-01-28
SI2827899T1 (sl) 2015-11-30
RU2649009C2 (ru) 2018-03-29

Similar Documents

Publication Publication Date Title
CY1116706T1 (el) Εμβολια προϊοντος συζευξης αντιγονου πολυσακχαριδιου γλυκολιπιδιου
CY1123769T1 (el) Νουκλεϊκα οξεα για την αγωγη αλλεργιων
CY1122073T1 (el) Μορια αντισωματος που εχουν εξειδικευση για τον ανθρωπινο οχ40
PH12021550318A1 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CY1121431T1 (el) Μορια αντισωματος που εχουν ειδικοτητα για τον ανθρωπινο οχ40
CY1120740T1 (el) Βελτιωμενα ευλογοϊικα εμβολια
CY1121998T1 (el) Συνδυασμενο εμβολιο pcv/mycoplasma hyopneumoniae
CY1120319T1 (el) Πρωτεϊνες συντηξης και εμβολια συνδυασμου που περιλαμβανουν haemophilus influenzae πρωτεϊνη ε και πιλινη α
CL2019000067A1 (es) Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos.
CY1120489T1 (el) Εμβολια για hsv-2
CY1121535T1 (el) Πρωτεϊνικα κατασκευασματα uspa2 και χρησεις αυτων
CY1117689T1 (el) Συνθεσεις που περιλαμβανουν πνευμονιοκοκκικα αντιγονα
BR112016015140A2 (pt) imunoglobulina com fabs in-tandem e usos das mesmas
CY1113760T1 (el) Εμβολιο
EA201691348A1 (ru) Однофлаконные вакцинные составы
EA201790239A1 (ru) Молекула-носитель для антигенов
EA201690857A1 (ru) Конъюгатные вакцины на основе сальмонеллы
MX2020012913A (es) Proteinas de consenso para el virus de la enfermedad de la fiebre aftosa (fmdv), secuencias de codificacion para estas y vacunas elaboradas a partir de estas.
MX363149B (es) Vacunas de nucleoproteina de la influenza.
BR112014020025A2 (pt) vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas
ES2503516R1 (es) Complejo inmunogénico para vacunación y método de obtención
CL2013001219A1 (es) Metodo para producir virus monoglucosilado de influenza; virus monoglucosilado del antígeno de influenza ha (virus completo o recombinante); uso del virus para preparar vacuna.
CU20150019A7 (es) Rotavirus humanos modificados
BR112014026812A8 (pt) Antígenos e combinações de antígenos
Surajkumar et al. Infection Control in Office-based Practices